507 related articles for article (PubMed ID: 23876384)
21. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
22. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
23. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake.
Tiwari R; Pathak K
Int J Pharm; 2011 Aug; 415(1-2):232-43. PubMed ID: 21640809
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of silybin-loaded nanostructured lipid carriers.
Jia LJ; Zhang DR; Li ZY; Feng FF; Wang YC; Dai WT; Duan CX; Zhang Q
Drug Deliv; 2010 Jan; 17(1):11-8. PubMed ID: 19941406
[TBL] [Abstract][Full Text] [Related]
25. Non-destructive methods of characterization of risperidone solid lipid nanoparticles.
Rahman Z; Zidan AS; Khan MA
Eur J Pharm Biopharm; 2010 Sep; 76(1):127-37. PubMed ID: 20470882
[TBL] [Abstract][Full Text] [Related]
26. Optimizing SLN and NLC by 2(2) full factorial design: effect of homogenization technique.
Severino P; Santana MH; Souto EB
Mater Sci Eng C Mater Biol Appl; 2012 Aug; 32(6):1375-9. PubMed ID: 24364934
[TBL] [Abstract][Full Text] [Related]
27. Optimization of linalool-loaded solid lipid nanoparticles using experimental factorial design and long-term stability studies with a new centrifugal sedimentation method.
Pereira I; Zielińska A; Ferreira NR; Silva AM; Souto EB
Int J Pharm; 2018 Oct; 549(1-2):261-270. PubMed ID: 30075252
[TBL] [Abstract][Full Text] [Related]
28. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
29. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization.
Liu J; Gong T; Wang C; Zhong Z; Zhang Z
Int J Pharm; 2007 Aug; 340(1-2):153-62. PubMed ID: 17428627
[TBL] [Abstract][Full Text] [Related]
30. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
31. Nanostructured lipid carriers as a delivery system of biochanin A.
Wang Q; Cheng H; Zhou K; Wang L; Dong S; Wang D; Chen W
Drug Deliv; 2013 Nov; 20(8):331-7. PubMed ID: 24111887
[TBL] [Abstract][Full Text] [Related]
32. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy.
Ferreira M; Chaves LL; Lima SA; Reis S
Int J Pharm; 2015 Aug; 492(1-2):65-72. PubMed ID: 26169145
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
34. Nanostructured Etodolac Carriers in Transdermal Gel: Optimization and Characterization.
Patil P; Shirkhedkar A
Pharm Nanotechnol; 2023 Jun; 11(3):276-293. PubMed ID: 36635925
[TBL] [Abstract][Full Text] [Related]
35. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
Neupane YR; Srivastava M; Ahmad N; Kumar N; Bhatnagar A; Kohli K
Int J Pharm; 2014 Dec; 477(1-2):601-12. PubMed ID: 25445972
[TBL] [Abstract][Full Text] [Related]
36. Post-insertion into Lipid NanoCapsules (LNCs): From experimental aspects to mechanisms.
Perrier T; Saulnier P; Fouchet F; Lautram N; Benoît JP
Int J Pharm; 2010 Aug; 396(1-2):204-9. PubMed ID: 20600733
[TBL] [Abstract][Full Text] [Related]
37. Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers.
Yang CR; Zhao XL; Hu HY; Li KX; Sun X; Li L; Chen DW
Chem Pharm Bull (Tokyo); 2010 May; 58(5):656-61. PubMed ID: 20460792
[TBL] [Abstract][Full Text] [Related]
38. [Preparation of podophyllotoxin nanostructured lipid carriers and its effects on immortalized human cervical epithelial cells with HPV infection in vitro].
Chong SB; Zeng K; Li GF; Ren F; Zhu XL; Zhou JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1023-8. PubMed ID: 21690061
[TBL] [Abstract][Full Text] [Related]
39. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
40. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]